Kumyang Green Power lifts Hyundai E&C contract value to KRW 33.21 billion in correction filing
Bitget2026/10/08 08:31Kumyang Green Power corrected a previously disclosed supply contract, citing a construction change order. Confirmed contract value revised to KRW 33.21 billion from KRW 32.37 billion. Sales exposure increased to 12.54% from 12.22%, based on 2025 consolidated revenue of KRW 264.78 billion. Project covers electrical installation work for the Shaheen ethylene facility construction package in Ulsan. Counterparty remains Hyundai Engineering & Construction; contract runs from April 22, 2024 to Nov. 30, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kumyang Green Power Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261008900615), on October 08, 2026, and is solely responsible for the information contained therein.
- Kumyang Green Power corrected a previously disclosed supply contract, citing a construction change order.
- Confirmed contract value revised to KRW 33.21 billion from KRW 32.37 billion.
- Sales exposure increased to 12.54% from 12.22%, based on 2025 consolidated revenue of KRW 264.78 billion.
- Project covers electrical installation work for the Shaheen ethylene facility construction package in Ulsan.
- Counterparty remains Hyundai Engineering & Construction; contract runs from April 22, 2024 to Nov. 30, 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
Itaúsa Q3 2026 recurring net profit rises 25% to R$ 5.06 billion year-on-year
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
Crypto prices
More
